WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will report its third-quarter 2026 financial results and provide an update on its dermatology drug development programs Thursday, Nov. 12, at 4:30 p.m. Eastern, giving investors an opportunity to assess the West Chester company’s commercial operations and clinical pipeline.
The results will cover the quarter ended Sept. 30, 2026, according to the company.
Verrica develops and commercializes treatments for dermatological conditions, including viral skin infections and non-melanoma skin cancers.
Its marketed product, YCANTH (VP-102), is an FDA-approved, healthcare professional-administered cantharidin treatment for molluscum contagiosum in adults and children ages 2 and older.
The contagious viral skin infection affects approximately 6 million people in the United States, primarily children.
Verrica is also developing YCANTH as a potential treatment for common warts, an additional indication that would expand the product’s clinical applications if approved.
The company’s oncology pipeline includes VP-315, also known as ruxotemitide, which it licensed from Lytix Biopharma ASA under a worldwide development and commercialization agreement.
The investigational therapy is being developed for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma.
Investors and other participants can join the Nov. 12 conference call by dialing 1-833-354-6854 or 1-785-838-9343 and providing the conference ID VERRICA. Participants are encouraged to connect 10 minutes before the scheduled start.
A live audio webcast will be available through the investor relations section of Verrica’s website at www.verrica.com.
The company will archive a webcast replay on its website for 90 days following the presentation.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.